QUAD vs SRPT

For growth investors, Sarepta Therapeutics, Inc.

(SRPT) is the stronger pick with 53. 0% revenue growth year-over-year, versus -9. 4% for Quad/Graphics, Inc. (QUAD). Sarepta Therapeutics, Inc. (SRPT) offers the better valuation at 9. 3x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Quad/Graphics, Inc. (QUAD) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Sarepta Therapeutics, Inc.

(SRPT) is the cheapest at 9. 3x versus Quad/Graphics, Inc. at 13. 6x. On forward P/E, Quad/Graphics, Inc. is actually cheaper at 6. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Quad/Graphics, Inc.

(QUAD) delivered a total return of +121. 2%, compared to -70. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: SRPT returned +30. 0% versus QUAD's -17. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Quad/Graphics, Inc.

(QUAD) is the lower-risk stock at 1. 03β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 97% more volatile than QUAD relative to the S&P 500. On balance sheet safety, Sarepta Therapeutics, Inc. (SRPT) carries a lower debt/equity ratio of 88% versus 3% for Quad/Graphics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sarepta Therapeutics, Inc.

(SRPT) is pulling ahead at 53. 0% versus -9. 4% for Quad/Graphics, Inc. (QUAD). On earnings-per-share growth, the picture is similar: Quad/Graphics, Inc. grew EPS 150. 5% year-over-year, compared to 140. 3% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 39. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Sarepta Therapeutics, Inc.

(SRPT) is the more profitable company, earning 12. 4% net margin versus 1. 1% for Quad/Graphics, Inc. — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SRPT leads at 11. 5% versus 4. 9% for QUAD. At the gross margin level — before operating expenses — SRPT leads at 83. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Quad/Graphics, Inc.

(QUAD) trades at 6. 0x forward P/E versus 7. 3x for Sarepta Therapeutics, Inc. — 1. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SRPT: 13. 0% to $24. 63.

In this comparison, QUAD (3.

9% yield) pays a dividend. SRPT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Quad/Graphics, Inc.

(QUAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), 3. 9% yield). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (QUAD: -17. 5%, SRPT: +30. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (QUAD (Industrials) and SRPT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: QUAD is a small-cap deep-value stock; SRPT is a small-cap high-growth stock. QUAD pays a dividend while SRPT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.